Chutes & Ladders — Mirati Therapeutics CMO, COO given the boot as FDA filing looms


Welcome to Chutes & Ladders this week, our roundup of hires, layoffs and retirements across the industry. Please send your store’s good or bad word to Kyle LaHucik, and we’ll feature it here at the end of each week.

As it prepares to file first drug with FDA, Mirati splits from medical and operational directors

Mirati Therapeutics
Joseph Levèque, MD and Daniel Faga are on the doorstep as Chief Medical Officers and Chiefs of Operations, respectively.

C-suite executives received the boot six weeks after new CEO David Meek took office. The company is trying to catch Amgen in the KRAS race with its drug adagrasib, which Mirati plans to ask the FDA for approval in the coming months. In place of the deceased executives, Mirati is looking for a CFO to oversee the marketing efforts. Fierce biotech

VC OrbiMed store poaches ex-CMO of Moderna for venture capital partner position

Tal Zaks, MD, Ph.D., is one of OrbiMed’s two new corporate partners.

Zaks has left Moderna in recent weeks, where he was chief medical officer after a six-year stint in biotechnology that has become the hallmark of the COVID-19 vaccine. Since revealing his departure plans in February, he has also served as a non-executive director at Teva Pharmaceuticals. OrbiMed has also hired Sheila gujrathi, MD, as a venture capital advisor. She was previously Executive Chairman of Ventyx Biosciences and CEO of Gossamer Bio until about a year ago. Fierce biotech

Lengo extends hiring wave with veteran Pfizer Turning Point vice president Brion Murray as senior vice president of research

Lengo Therapeutics
Brion Murray, Ph.D., is the new senior vice president of research.

Murray joined early-stage biotechnology from San Diego from Turning Point Therapeutics, where he was vice president for cancer biology and translational research. He was also a researcher at Pfizer before, where he worked on cancer therapies like Ibrance, Vizimpro and others. His hiring comes after other additions to the team, including a head of development and SVP in other functions. Fierce biotech

> Derek chalmers spent 17 years bringing Cara Therapeutics’ first drug to the FDA finish line. Now, three months after getting regulatory approval, he’s headed for the door and will be replaced by US CEO Leo Pharma Christophe posner. Fierce biotech

> Bayer bugged Christophe Koenen as the new global head of clinical development and operations for its R&D unit. Koenen starts on New Years Day after serving as Chief Medical Officer at Otsuka Pharmaceutical. Fierce biotech

> Testing Network Provider Named Associate Professor at Harvard Jeffrey Brown, Ph.D., its scientific director. Fierce biotech

> Autoimmune biotechnology named Imcyse Gene Mack its CFO after overseeing the finances of OncoC4. Exit

> Frank Wiegand, MD, Ph.D., is now Chief Medical Officer of Beckley Psytech, a neuropsychiatric biotechnology, after more than 20 years at Johnson & Johnson’s Janssen, most recently as vice president of global medical affairs for neurosciences. Exit

> Inflammatory Diseases and Pain Biotech 180 Named Life Sciences Quan Vu as Chief Operating / Business Officer after having been a CBO / CFO consultant at LS Associates. Exit

> Niels Plath , Ph.D., is the new Scientific Director of Neurodegenerative Biotechnology Muna Therapeutics after serving as Acting Head of Global Research at Lundbeck. Exit

> Hiring of bioelectronics company SetPoint Medical Amy Derosier as vice president of clinical affairs after leading clinical development for Torax Medical. Exit

> Jean Long is the new CFO and Jielun zhu transitions to the role of director of strategy at I-Mab, a biological biotechnology. Exit

> Jennifer Minai-Azary left Millendo Therapeutics, where she was CFO, to take on the same role at Context Therapeutics. Cancer biotechnology has also hired Alex Levit as General Counsel after being Vice President and Deputy General Counsel at OptiNose. Exit

> Christophe Lemon, Ph.D., is the new Scientific Director of Fusion Pharmaceuticals after serving as Executive Director of Radioligand Drug Discovery at Novartis. Exit

> Katarina Jelic Maiboe, Ph.D., is the new Head of Regulatory Affairs at HMNC Brain Health after serving as Senior Director of Regulatory Affairs at Ascendis Pharma. Exit

> Bioventus named Sharon klugewicz his SVP of Quality and Regulatory Affairs after having served as Director of Operations at Misonix since 2019. Exit

> TopAlliance, subsidiary of Junshi Biosciences named Virginie Ellen Maher, MD, its vice president of medical sciences after serving as an executive director at biopharmaceutical consultancy firm DataRevive and previously spending nearly 20 years at the FDA. Exit

> GBS named Steven boyages, Ph.D., as interim CEO as the board seeks a permanent CEO. Exit

> Jinky ang rosselli was promoted to Director of Data and Knowledge at BioCryst Pharmaceuticals, where she has worked since 2015. Exit

> Akouos precision genetic medicine company named Stacy Award its CTO after serving as Senior Vice President of Technical Operations at Ziopharm Oncology. Exit

> David Renas will step down as CFO of Women’s Reproductive Health Biotechnology ObsEva, effective January 5. Exit

> Tango Therapeutics appointed Marc Rudoltz, MD, his chief medical officer, and Doug barry to the post of Advocate General. Rudoltz was Marketing Director for Deciphera Pharmaceuticals and Constellation Pharmaceuticals prior to his role at MSR Healthcare Consultants. Barry was previously Vice President of Corporate Law at Alexion Pharmaceuticals. Exit

> EyePoint Pharmaceuticals appointed Jay duck, MD, its COO after serving as part-time Strategic Scientific Director since 2020. Exit

> Liver BioLife and Neurodegenerative Biotechnology Named Joseph palumbo, MD, his new Chief Medical Officer after holding the same position at Zynerba Pharmaceuticals. Exit

> Adrien Hepner, MD, Ph.D., joins Coya Therapeutics as Chief Medical Officer, and Greg Mac Michael, Ph.D., is the new technical director of Treg Biotechnology. Exit

> Bluestar Genomics named Jim vaughn its commercial director after having held a similar position at Genomic Health.

> Pamela fisher was appointed Director of Diversity & Inclusion at Bristol Myers Squibb after leading Diversity & Inclusion and Global Strategic Partnerships at Johnson & Johnson. Exit

> Stephen dodge is now Global Head of Medical Affairs and Senior Vice President at Madrigal after serving as Senior Vice President at Intercept Pharmaceuticals. Exit (PDF)

> Stephanie Brown will be president of the North America division of Santhera Pharmaceuticals from December 1. She was previously SVP and Head of Rare Diseases for the North America unit of Ipsen Pharmaceuticals. Exit

> Stewart campbell was promoted to EVP and President of North America for Ipsen. He joined the company as SVP and Head of Oncology earlier this year after 14 years with Roche at Genentech. Exit

> NeuroBo Pharmaceuticals appointed Gil Prize, MD, its President and CEO as Richard kang, Ph.D., resigns later this month. Kang will remain on the board and consult with the company for up to a year. Exit

> Quoin Pharmaceuticals named Gordon dunn its CFO after having held the same position at Qured. Exit

> Elie Hananiah, Ph.D., was appointed Vice President of Process Development for Viral Vector Technology at Avid Bioservices after serving as Director of Upstream Process Development for Fujifilm Diosynth Biotechnologies. Exit

Leave A Reply

Your email address will not be published.